Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

356
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
356
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Hematopoiesis01:21

Hematopoiesis

5.4K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

The oncologist·2026
Same author

Next-Generation Biomaterials for Neuroendovascular Devices: The Potential of Niobium, Tantalum, and Advanced Cobalt Alloys.

World neurosurgery·2026
Same author

Comparative evaluation of open flap debridement with or without injectable platelet-rich fibrin in chronic periodontitis treatment.

Bioinformation·2026
Same author

Knowledge, Attitude, and Awareness of Adolescents on the Emergency Management of Traumatic Dental Injuries.

Dentistry journal·2026
Same author

Molecular Pathways of Microbiota-derived Neuromodulation: An Integrative View.

Current neurovascular research·2026
Same author

A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jul 16, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K

Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned.

Chase V West1, Matthew J Butler2, Supreet Kaur2

  • 1Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX.

JCO Oncology Practice
|September 15, 2023
PubMed
Summary

Classical hematology (CH) referrals constitute nearly 40% of all hematology-oncology referrals at a National Cancer Institute (NCI)-designated cancer center. Anemia and thrombotic disorders were the most frequent CH referral reasons.

More Related Videos

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.9K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Related Experiment Videos

Last Updated: Jul 16, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.9K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Area of Science:

  • Hematology
  • Oncology
  • Healthcare Management

Background:

  • Referrals to hematology clinics often include classical hematology (CH) cases.
  • Understanding the volume and types of CH referrals is crucial for optimizing patient care within cancer centers.

Purpose of the Study:

  • To determine the spectrum and volume of classical hematology (CH) referrals to a National Cancer Institute (NCI)-designated cancer center (CC).
  • To inform planning for effective and equitable care delivery for patients with CH conditions.

Main Methods:

  • A single referral office at an academic CC in Bexar County, TX, handled all adult hematology referrals.
  • Nonmalignant hematology (MH) referrals were triaged daily from October 1, 2021, to September 30, 2022.
  • Declined referrals were included in the analysis; electronic consultations were excluded.

Main Results:

  • 1,945 CH referrals were received over 12 months, with 3.9% declined.
  • CH referrals represented 39% of all hematology-oncology and 71% of all hematology referrals.
  • Anemia (26%) and thrombotic disorders (21%) were the most common CH referral categories.
  • Video visits accounted for 23% of CH referrals.

Conclusions:

  • Classical hematology referrals comprise a significant portion (nearly 40%) of all referrals to hematology and medical oncology at NCI-designated cancer centers.
  • Effective management of CH patients can improve overall care for both CH and cancer-focused conditions.